4 results
Primary Objective:The primary objective is to demonstrate the efficacy of 1 or 2 dose regimens of HZN-825 versus placebo in subjects with diffuse cutaneous SSc, as determined by a comparison of change in forced vital capacity (FVC) % predicted after…
Core phase: The overall objective of the core phase is to investigate the efficacy, safety and tolerability of 2 dose regimens of HZN-825, a selective antagonist of lysophosphatidic acid receptor-1 (LPAR1), administered once daily (QD) or twice…
The aim of this study is to evaluate cardio-protective effects of xenon inhalation in humans and to identify enzymes contributing to cardio-protection influenced by xenon in patients scheduled for CABG surgery.
The aim of this study is to evaluate the immediate effect of xenon inhalation on cardiac performance in patients scheduled for CABG surgery in comparison with the effect induced by sevoflurane inhalation.